Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Head & Neck · 2025
DOI: 10.1002/hed.27892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Beatriz Cirauqui Cirauqui und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Catalan Institute of Oncology (ICO), Badalona, Spain. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Paclitaxel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive disease with poor prognosis. It is known that the activation of STAT3 signaling pathways promotes the development and progression of this neoplasia and it has been described the role of PTPRT as a negative regulator of STAT3. Then, we have evaluated the impact of them as biomarkers of outcome in a series of patients with recurrent and/or metastatic SCCHN treated with weekly paclitaxel‐plus‐cetuximab (ERBITAX) regimen. Patients and methods Between 2008 and 2017, 52 patients with recurrent/metastatic SCCHN were treated with ERBITAX at our center, 34 of whom had available tumor samples. Phosphorylated STAT3 (pSTAT3) protein expression was analyzed by immunohistochemistry, STAT3 mRNA expression by qPCR, and PTPRT promoter methylation by methylation‐specific PCR. Molecular results were correlated with response rate (RR), progression‐free survival (PFS), and overall survival (OS). Results pSTAT3 overexpression was detected in 67% and PTPRT promoter hypermethylation in 41% of tumor samples. PTPRT promoter hypermethylation showed a trend towards an association with lower RR (21% vs. 60%; p = 0.06). A lower RR was also observed in patients with pSTAT3 overexpression (36% vs. 54%) and in those with high STAT3 mRNA levels (43% vs. 64%), but these differences did not reach statistical significance. PTPRT promoter hypermethylation correlated with pSTAT3 overexpression ( p = 0.009) but not with STAT3 mRNA overexpression. OS and PFS was shorter in patients with activated STAT3, but the difference did not reach statistical significance.
Conclusions
Although this was a relatively small retrospective study, it provides preliminary indications of the potential role of the STAT3 pathway on outcome in SCCHN and confirms that PTPRT acts as a negative regulator of STAT3. Our findings warrant investigation in a larger patient cohort to determine if inactivating this pathway through specific targeted treatments could improve outcomes in recurrent/metastatic SCCHN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Catalan Institute of Oncology (ICO), Badalona, Spain.
- Badalona Applied Research Group in Oncology (BARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
- Translational Program in Cancer Research (CARE), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
- Head and Neck Functional Unit, Catalan Institute of Oncology (ICO), Badalona, Spain.
- Department of Pathology, Germans Trias i Pujol Hospital, Badalona, Spain.
- Molecular Biology Unit, Hematology Laboratory, Catalan Institute of Oncology (ICO), Badalona, Spain.
ORCID-Profile: Beatriz Cirauqui Cirauqui
Zitieren
APA
Cirauqui, B. C., Peguera, A. B., Pi-Sunyer, A. Q., Ferrando-Díez, A., Serrano, J. L. R., Viñolas, M. D., García, I. T., García, V. Q., Oukadour, I. C., Valencia, A. G., Vergara, P. H., de Aguirre Egaña, I., Herrero, C. Q., Carbonell, O. M., Paradís, A. L., Esteve, A., Vila, M. M., Rosell, R., Martínez-Cardús, A., & Mesía, R. (2025). Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck. https://doi.org/10.1002/hed.27892
Vancouver
Cirauqui BC, Peguera AB, Pi-Sunyer AQ, Ferrando-Díez A, Serrano JLR, Viñolas MD, et al. Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck. 2025. doi:10.1002/hed.27892
BibTeX
@article{Cirauqui2025,
author = {Cirauqui, Beatriz Cirauqui and Peguera, Adrià Bernat and Pi-Sunyer, Ariadna Quer and Ferrando-Díez, Angelica and Serrano, Jose Luis Ramírez and Viñolas, Marta Domenech and García, Iris Teruel and García, Vanesa Quiroga and Oukadour, Imane Chaib and Valencia, Andrea González and Vergara, Pilar Hernández and de Aguirre Egaña, Itziar and Herrero, Cristina Queralt and Carbonell, Oscar Mesía and Paradís, Assumpció López and Esteve, Anna and Vila, Mireia Margelí and Rosell, Rafael and Martínez-Cardús, Anna and Mesía, Ricard},
title = {Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.27892}
}
EUVIMED